Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
NCT02824094 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2017-07-21
Summary
Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.
Conditions
- Neoplasms
- Carcinoma, Non-Small-Cell Lung
Interventions
- DRUG
-
Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Japan
Study Locations
More Related Trials
-
Study of Poziotinib in Japanese Patients With NSCLC
NCT04402008 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Rollover Protocol of Dacomitinib For Patients In Japan
NCT02382796 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1
NCT04718012 ·Status: COMPLETED
-
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
NCT02499614 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
NCT04084717 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866 ·Status: COMPLETED ·Phase: PHASE3
-
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
NCT02404675 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC
NCT00144989 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
NCT01597258 ·Status: COMPLETED
-
Study on the Mechanism of Acquired Resistance of Entrectinib
NCT07199959 ·Status: RECRUITING
-
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
NCT05735327 ·Status: ACTIVE_NOT_RECRUITING
-
Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients
NCT05792644 ·Status: COMPLETED ·Phase: NA
-
Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation
NCT01637597 ·Status: UNKNOWN
-
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
NCT04979988 ·Status: COMPLETED
-
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
NCT02679170 ·Status: COMPLETED
-
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
NCT02820116 ·Status: UNKNOWN ·Phase: PHASE2
-
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
NCT03439215 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
NCT06934590 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
NCT06694129 ·Status: NOT_YET_RECRUITING
-
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
NCT02876978 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
NCT06678555 ·Status: ACTIVE_NOT_RECRUITING